Annals of Surgical Oncology

, Volume 20, Issue 7, pp 2304–2310 | Cite as

Population-Based Outcome of Stage IA-IIA Resected Gastric Adenocarcinoma: Who Should Get Adjuvant Treatment?

  • Jason S. Gold
  • Riad H. Al Natour
  • Mandeep S. Saund
  • Charles Yoon
  • Ashish M. Sharma
  • Qin Huang
  • Valia A. Boosalis
  • Edward E. Whang
Gastrointestinal Oncology

Abstract

Background

The benefit of adjuvant treatment in gastric adenocarcinoma was demonstrated by randomized, controlled trials of patients with locally advanced tumors. Thus, its role for stage IIB-IIIC disease is widely accepted. We aimed to identify patients with stage IA-IIA gastric adenocarcinoma who have a poor prognosis and thus may benefit from adjuvant treatment.

Methods

Patients with gastric adenocarcinoma who underwent surgical resection with pathological evaluation of ≥15 lymph nodes and had available disease-specific survival (DSS) data were identified from the Surveillance Epidemiology and End Results Registry. Survival differences were evaluated with the log-rank test and Cox multivariate analysis.

Results

Stage and TN grouping strongly predicted DSS (P < 0.001, P < 0.001). Stage IA tumors had an excellent outcome: 91 ± 1.2 % 5-year DSS. The TN groupings of stages IB and IIA had the next best outcomes with 5-year DSS from 66 ± 4.6 % to 81 ± 2.3 %. Older age (P < 0.001), higher grade (P = 0.004), larger tumor size (P < 0.001), and proximal tumor location (P < 0.001) were independent predictors of worse DSS in stage IB-IIA tumors. We devised a risk stratification scheme for stage IB-IIA tumors where 1 point was assigned for age >60 years, tumor size >5 cm, proximal tumor location, and grade other than well-differentiated. Five-year DSS was 100 % for patients with 0 points; 86 ± 4.3 %, 1 point; 76 ± 3 %, 2 points; 72 ± 2.8 %, 3 points; and 48 ± 4.9 %, 4 points (P < 0.001).

Conclusions

Patients with stage IB-IIA gastric adenocarcinoma and ≥2 adverse features (age >60 years, tumor size >5 cm, proximal location, and high-grade) have 5-year DSS ≤76 %. Adjuvant therapy may be warranted for these patients.

Keywords

Gastric Cancer Adjuvant Treatment Gastric Adenocarcinoma Serosal Invasion Resected Gastric Cancer 

Notes

Acknowledgments

This work is supported by the Department of Veterans Affairs Office of Research and Development through a Career Development Award-2 (JSG).

Disclosures

No Disclosures.

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedCrossRefGoogle Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.PubMedCrossRefGoogle Scholar
  3. 3.
    Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–73.PubMedCrossRefGoogle Scholar
  4. 4.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.PubMedCrossRefGoogle Scholar
  5. 5.
    GASTRIC Group, Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37.Google Scholar
  6. 6.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.PubMedCrossRefGoogle Scholar
  7. 7.
    Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.PubMedCrossRefGoogle Scholar
  8. 8.
    Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Nakajima T, Kinoshita T, Nashimoto A, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg. 2007;94(12):1468–76.PubMedCrossRefGoogle Scholar
  10. 10.
    Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer. 2001;84(12):1602–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Kooby DA, Suriawinata A, Klimstra DS, Brennan MF, Karpeh MS. Biologic predictors of survival in node-negative gastric cancer. Ann Surg. 2003;237(6):828-35; discussion 835–7.PubMedGoogle Scholar
  13. 13.
    Baiocchi GL, Tiberio GA, Minicozzi AM, et al. A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Ann Surg. 2010;252(1):70–3.PubMedCrossRefGoogle Scholar
  14. 14.
    Stomach. In: Edge SB, Byrd DR, Compton CC, et al., eds. AJCC cancer staging manual. 7th edn. New York: Springer; 2010:120.Google Scholar
  15. 15.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–62.CrossRefGoogle Scholar
  16. 16.
    Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28(35):5210–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer. 2000;88(4):921–32.PubMedCrossRefGoogle Scholar
  18. 18.
    NCCN Practice Guidelines in Oncology. Gastric Cancer. v2.2011. www.nccn.org.
  19. 19.
    Knight G, Earle CC, Cosby R, et al. Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America. Gastric Cancer. 2012 Mar 31.Google Scholar
  20. 20.
    Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og ppfølging av ventrikkelcancer (kreft i magesekken). www.helsedirektoratet.no.
  21. 21.
    Landelijke werkgroep Gastro-intestinale Tumoren. Maagcarcinoom v1.0. www.oncoline.nl.
  22. 22.
    Dudeja V, Habermann EB, Abraham A, Zhong W, Parsons HM, Tseng JF, Al-Refaie WB. Is there a role for surgery with adequate nodal evaluation alone in gastric adenocarcinoma? J Gastrointest Surg. 2012;16(2):238–46; discussion 246–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Coburn NG, Govindarajan A, Law CH, et al. Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients. Ann Surg Oncol. 2008;15(2):500–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Wang J, Dang P, Raut CP, et al. Comparison of a lymph node ratio-based staging system with the 7th AJCC system for gastric cancer: analysis of 18,043 patients from the SEER database. Ann Surg. 2012;255(3):478–85.PubMedCrossRefGoogle Scholar
  25. 25.
    Warneke VS, Behrens HM, Hartmann JT, et al. Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging system. J Clin Oncol. 2011;29(17):2364–71.PubMedCrossRefGoogle Scholar
  26. 26.
    Kattan MW, Karpeh MS, Mazumdar M, et al. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003;21(19):3647–50.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Jason S. Gold
    • 1
    • 2
    • 3
  • Riad H. Al Natour
    • 1
    • 2
    • 3
  • Mandeep S. Saund
    • 2
    • 3
  • Charles Yoon
    • 2
    • 3
  • Ashish M. Sharma
    • 4
    • 5
  • Qin Huang
    • 3
    • 6
  • Valia A. Boosalis
    • 4
    • 5
  • Edward E. Whang
    • 1
    • 2
    • 3
  1. 1.Surgery Services, VA Boston Healthcare SystemWest RoxburyUSA
  2. 2.Brigham and Women’s HospitalBostonUSA
  3. 3.Harvard Medical SchoolBostonUSA
  4. 4.Medicine Services, VA Boston Healthcare SystemWest RoxburyUSA
  5. 5.Boston University School of MedicineBostonUSA
  6. 6.Pathology ServicesVA Boston Healthcare SystemWest RoxburyUSA

Personalised recommendations